FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176918837> ?p ?o ?g. }

• W3176918837 abstract "Heme Oxygenase-1 (HO-1) catalyzes the enzymatic degradation of heme with the simultaneous release of CO, Fe2+and biliverdin. Uveal melanoma (UM) is the most common primary intraocular tumor in adults, with about 1200–1500 new cases occurring per year in the U.S. Unfortunately, no chemotherapeutic regimen or immunotherapy has been demonstrated to be effective in these patients. The aim of the present study was to characterize in vitro the role of HO-1 and its enzymatic byproducts in UM in cancer progression. Such results were further confirmed in a series of UM human biopsies (n=80) retrieved from our database. The study was conducted according to the basic principles of the declaration oh Helsinki. Cell proliferation and colony formation capacity were evaluated by Xcelligence technology and clonogenic assay. Cells were also treated with Hemin (10 μM) and/or VP13/47 (100 μM) as potent pharmacological inducer and inhibitor of HO-1 respectively. HO-1 protein expression was evaluated by real time PCR and immunocytochemistry. In a separate set of experiments, we also tested the biological effects of HO activity byproducts by treating cells with CO releasing molecules (CORM-3 and CORM-A1 25 μM) and biliverdin (25 μM). Our results showed that hemin significantly increased (46.34±4.5-fold increase vs untreated cells, p<0.01) HO-1 gene and protein expression resulting in a significant increase in cell proliferation (2.3±0.3 fold increase vs untreated cells, p<0.01) and colony formation capacity (1003±20 colonies in treated cells vs 503±14 in untreated cells). Similarly, hemin treatment resulted in a significant decrease of doubling time (20.42±2.3 h vs 32.74±1.2 h, p<0.01) and this effect was abolished by concomitant treatment with VP13/47 (49.71±3.9, p<0.01). Consistently, CORMs treatments significantly decreased doubling time (13.8±2.9 h and 11.5±1.5 h for CORMA1 and CORM3 respectively, p<0.01 vs untreated cells). Our results also showed that VP13/47 reversed the proliferative effect of hemin and strongly inhibited growth when used alone. Furthermore, we observed similar proliferative effects of hemin with CORMs but not with biliverdin alone. Interestingly, CORMs treatment abolished the antiproliferative effect of VP13/47 whereas biliverdin showed no effects. The direct correlation of HO-1 with tumor growth and progression was further confirmed in human biopsies showing that HO-1 expression significantly correlated with the expression of p16, a well-established biomarker of cell proliferation. In conclusion, our results showed that HO-1 derived CO is required for UM growth and progression and the HO system may therefore represent a good candidate to be exploited as a target for new chemotherapic agents. Support or Funding Information This work was supported by FIR 2016–2018 from the University of Catania. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal." @default.
• W3176918837 created "2021-07-05" @default.
• W3176918837 creator A5000669363 @default.
• W3176918837 creator A5005242626 @default.
• W3176918837 creator A5026039152 @default.
• W3176918837 creator A5027161000 @default.
• W3176918837 creator A5031489964 @default.
• W3176918837 creator A5036314052 @default.
• W3176918837 creator A5042296886 @default.
• W3176918837 creator A5061835885 @default.
• W3176918837 creator A5064782017 @default.
• W3176918837 creator A5066691562 @default.
• W3176918837 creator A5070063314 @default.
• W3176918837 creator A5072417532 @default.
• W3176918837 creator A5076603987 @default.
• W3176918837 creator A5084855762 @default.
• W3176918837 date "2019-04-01" @default.
• W3176918837 modified "2023-09-23" @default.
• W3176918837 title "Heme Oxygenase‐1‐Derived Carbon Monoxide Promotes Growth and Progression in Uveal Melanoma" @default.
• W3176918837 doi "https://doi.org/10.1096/fasebj.2019.33.1_supplement.790.7" @default.
• W3176918837 hasPublicationYear "2019" @default.
• W3176918837 type Work @default.
• W3176918837 sameAs 3176918837 @default.
• W3176918837 citedByCount "0" @default.
• W3176918837 crossrefType "journal-article" @default.
• W3176918837 hasAuthorship W3176918837A5000669363 @default.
• W3176918837 hasAuthorship W3176918837A5005242626 @default.
• W3176918837 hasAuthorship W3176918837A5026039152 @default.
• W3176918837 hasAuthorship W3176918837A5027161000 @default.
• W3176918837 hasAuthorship W3176918837A5031489964 @default.
• W3176918837 hasAuthorship W3176918837A5036314052 @default.
• W3176918837 hasAuthorship W3176918837A5042296886 @default.
• W3176918837 hasAuthorship W3176918837A5061835885 @default.
• W3176918837 hasAuthorship W3176918837A5064782017 @default.
• W3176918837 hasAuthorship W3176918837A5066691562 @default.
• W3176918837 hasAuthorship W3176918837A5070063314 @default.
• W3176918837 hasAuthorship W3176918837A5072417532 @default.
• W3176918837 hasAuthorship W3176918837A5076603987 @default.
• W3176918837 hasAuthorship W3176918837A5084855762 @default.
• W3176918837 hasConcept C153911025 @default.
• W3176918837 hasConcept C181199279 @default.
• W3176918837 hasConcept C185592680 @default.
• W3176918837 hasConcept C2776217839 @default.
• W3176918837 hasConcept C2776253728 @default.
• W3176918837 hasConcept C2777658100 @default.
• W3176918837 hasConcept C2777723881 @default.
• W3176918837 hasConcept C2779059073 @default.
• W3176918837 hasConcept C2779219270 @default.
• W3176918837 hasConcept C2780428090 @default.
• W3176918837 hasConcept C2780827179 @default.
• W3176918837 hasConcept C502942594 @default.
• W3176918837 hasConcept C55493867 @default.
• W3176918837 hasConcept C62112901 @default.
• W3176918837 hasConcept C71924100 @default.
• W3176918837 hasConcept C86803240 @default.
• W3176918837 hasConceptScore W3176918837C153911025 @default.
• W3176918837 hasConceptScore W3176918837C181199279 @default.
• W3176918837 hasConceptScore W3176918837C185592680 @default.
• W3176918837 hasConceptScore W3176918837C2776217839 @default.
• W3176918837 hasConceptScore W3176918837C2776253728 @default.
• W3176918837 hasConceptScore W3176918837C2777658100 @default.
• W3176918837 hasConceptScore W3176918837C2777723881 @default.
• W3176918837 hasConceptScore W3176918837C2779059073 @default.
• W3176918837 hasConceptScore W3176918837C2779219270 @default.
• W3176918837 hasConceptScore W3176918837C2780428090 @default.
• W3176918837 hasConceptScore W3176918837C2780827179 @default.
• W3176918837 hasConceptScore W3176918837C502942594 @default.
• W3176918837 hasConceptScore W3176918837C55493867 @default.
• W3176918837 hasConceptScore W3176918837C62112901 @default.
• W3176918837 hasConceptScore W3176918837C71924100 @default.
• W3176918837 hasConceptScore W3176918837C86803240 @default.
• W3176918837 hasFunder F4320322690 @default.
• W3176918837 hasIssue "S1" @default.
• W3176918837 hasLocation W31769188371 @default.
• W3176918837 hasOpenAccess W3176918837 @default.
• W3176918837 hasPrimaryLocation W31769188371 @default.
• W3176918837 hasRelatedWork W1790250746 @default.
• W3176918837 hasRelatedWork W1832224497 @default.
• W3176918837 hasRelatedWork W1974297472 @default.
• W3176918837 hasRelatedWork W2019209742 @default.
• W3176918837 hasRelatedWork W2032552232 @default.
• W3176918837 hasRelatedWork W2055317690 @default.
• W3176918837 hasRelatedWork W2091867501 @default.
• W3176918837 hasRelatedWork W2097480577 @default.
• W3176918837 hasRelatedWork W2162202064 @default.
• W3176918837 hasRelatedWork W2335435488 @default.
• W3176918837 hasVolume "33" @default.
• W3176918837 isParatext "false" @default.
• W3176918837 isRetracted "false" @default.
• W3176918837 magId "3176918837" @default.
• W3176918837 workType "article" @default.